GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomed SA (WAR:GEN) » Definitions » Return-on-Tangible-Asset

Genomed (WAR:GEN) Return-on-Tangible-Asset : 13.36% (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Genomed Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Genomed's annualized Net Income for the quarter that ended in Sep. 2024 was zł1.42 Mil. Genomed's average total tangible assets for the quarter that ended in Sep. 2024 was zł10.63 Mil. Therefore, Genomed's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was 13.36%.

The historical rank and industry rank for Genomed's Return-on-Tangible-Asset or its related term are showing as below:

WAR:GEN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 0.06   Med: 6.31   Max: 23.35
Current: 8.19

During the past 13 years, Genomed's highest Return-on-Tangible-Asset was 23.35%. The lowest was 0.06%. And the median was 6.31%.

WAR:GEN's Return-on-Tangible-Asset is ranked better than
81.06% of 227 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.35 vs WAR:GEN: 8.19

Genomed Return-on-Tangible-Asset Historical Data

The historical data trend for Genomed's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomed Return-on-Tangible-Asset Chart

Genomed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.01 4.35 12.19 3.27 8.27

Genomed Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.71 48.43 -21.70 -6.62 13.36

Competitive Comparison of Genomed's Return-on-Tangible-Asset

For the Diagnostics & Research subindustry, Genomed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomed's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Genomed's Return-on-Tangible-Asset falls into.



Genomed Return-on-Tangible-Asset Calculation

Genomed's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=0.926/( (10.37+12.03)/ 2 )
=0.926/11.2
=8.27 %

Genomed's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=1.42/( (10.494+10.76)/ 2 )
=1.42/10.627
=13.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Genomed  (WAR:GEN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Genomed Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Genomed's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomed Business Description

Traded in Other Exchanges
N/A
Address
Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.